Every Company has raised $55 million to scale its production of precision fermented egg proteins, aiming for a nationwide rollout in the US. The San Francisco biotech company plans to expand manufacturing capacity, move towards profitability, and tap into the $270 billion egg market, especially in the high-volume bakery segment, with its functional, shelf-stable, and animal-free alternatives.

Investors in Every's Series D funding round include McWin Capital Partners and Main Sequence, among others. The ongoing bird flu virus has affected egg availability and prices worldwide, leading some to turn to plant-based alternatives. With increasing interest in egg alternatives due to price hikes and shortages, Every aims to provide accessible and versatile products to meet growing demand.

The funding will allow Every to make its products available in every state, city, and grocery store, according to CEO Arturo Elizondo. With the potential for stable and cost-effective egg replacements, the company is set to make a significant impact on the food market, offering innovative solutions as demand for alternatives continues to rise.